Astrazeneca Pharma India Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Astrazeneca Pharma India Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹7,416

Market cap₹20.3K Cr

P/E106.0

Published17 Jul 2026

What the Q1 FY26 call signalled

3 of 4 strong

RevenueRank 2

MarginRank 3

CapexYes

Order bookYes

Not discussed on this call: fundraise.

The short version

AstraZeneca Pharma India expects robust future growth driven primarily by oncology and biopharmaceutical portfolios. The Company reported a 32% revenue growth in FY 2024-25 and a 25% growth in profit before exceptional items and tax, signaling strong momentum.

From Astrazeneca Pharma India Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Rank 2

AstraZeneca Pharma India expects robust future growth driven primarily by oncology and biopharmaceutical portfolios.
Company plans multiple new product launches over the coming years, including rare disease products like Soliris.
The rare disease segment is an emerging focus area, aiming to build awareness and diagnosis capabilities in India, with potential to represent 15-16% of sales globally.
Growth in oncology has been phenomenal, with cancer portfolio currently constituting around 70%-75% of sales; diversification efforts are ongoing to balance this.
Revenue growth recorded was 32% in FY 2024-25; management is confident in sustaining high growth, with aspirations to double turnover every two years leading up to 2030.
AstraZeneca India aims to become a billion-dollar company by 2030, contributing about 1% of the global portfolio.
R&D investments and strategic marketing efforts will continue to support scaling and innovation.
The overall vision projects "sky is the limit" as long as patient-centric innovation and cause commitment continues.

Profitability & Margins

The Company reported a 32% revenue growth in FY 2024-25 and a 25% growth in profit before exceptional items and tax, signaling strong momentum.
Earnings per share (EPS) before exceptional items increased by 25%, despite a reduction after exceptional items due to strategic one-off costs.
Management is confident in continued growth driven by innovative product launches, particularly in Oncology and Biopharmaceuticals.
The rare diseases portfolio, though early-stage, is expected to grow steadily, contributing meaningfully over the next decade.
Investments in marketing, clinical trials, and logistics may increase operating costs in the short term but are aimed at sustaining long-term growth.
CAPEX and R&D investments will be aligned with growth plans, ensuring the introduction of new products benefiting patients in India.
The vision is robust growth without specifying exact figures, with a focus on expanding the product portfolio and market leadership.
Inventory build-up aligns with expected future demand, supporting sales growth and operational readiness.

See what Astrazeneca Pharma India Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

The Company continues to evaluate investments needed in India periodically.
As a global company committed to India, AstraZeneca plans to make the right level of CAPEX investments over the next several years aligned with its plans for India.
There is a focus on supporting growth through activities like marketing, medical personnel, and logistics, which impact costs.
Investment in clinical trials, especially Phase IV trials for new product launches, is ongoing.
No specific CAPEX figures or projects were detailed, but the assurance is given that strategic and appropriate investments will be made as required.

Fundraising & Capital Structure

- No explicit mention of any current or future fundraising plans through debt or equity in the provided pages. - The Company is described as a "zero debt Company" as of 2024-2025 (Page 21). - The leadership affirms ongoing evaluation of investments, CAPEX, and resource allocation, but no specific fundraising activity is detailed (Page 22). - Shareholders inquire about CAPEX plans and cash utilization; management assures prudent investments but does not indicate raising capital via debt or equity (Page 22). - Dividend increases and discussions around cost management imply internal funding is currently sufficient (Page 21). - There are no comments on issuing bonus shares or rights issues beyond shareholder suggestions, but no commitments from management (Page 21, 19). In summary, AstraZeneca Pharma India Limited currently holds zero debt and has not disclosed any plans for fundraising via debt or equity.

See what Astrazeneca Pharma India Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Yes

The provided pages of the AstraZeneca Pharma India Limited document do not contain specific information regarding the current or expected order book or pending orders. The discussion primarily revolves around: - Financial performance and growth outlook. - Questions from shareholders related to products, CAPEX plans, R&D expenditure. - Inventory levels and their relation to growth plans. - Strategic focus on Oncology, Biopharmaceuticals, and Rare Diseases. - Shareholders' queries on dividends, share price, and company vision. No explicit details or figures related to order book or pending orders are mentioned in the content from pages 15 to 23.

How does Astrazeneca Pharma India Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAstrazeneca Pharma India Ltd

Rev 2Mar 3

See where Astrazeneca Pharma India Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

Astrazeneca Pharma India Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹579 Cr, net profit ₹45 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Astrazeneca Pharma India Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Sigachi Indust. (Q1 FY26)
INR 60 crores from Hyderabad plant in next 6 months, with some recovery from other units (Dahej, Jhagadia). Key concall takeaways from Sigachi Industries Ltd's…
Sai Life (Q1 FY26)
Sai Life Sciences reported a strong Q1 FY'26 with revenue up 77% YoY, driven mainly by CDMO (113% growth) and CRO (38% growth). Key concall takeaways from Sai…
Cipla Ltd (Q1 FY26)
One Africa business grew 11% YoY, with continued focus on expansion. Key concall takeaways from Cipla's Q1 FY26 earnings call — and how it ranks against sector…
Anthem Bioscienc (Q1 FY26)
Capacity utilization in custom synthesis is around 70%, with expansions ongoing, indicating potential for further revenue growth. Key concall takeaways from…

Compare:vs Sun Pharmaceutical Industries Ltd vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Astrazeneca Pharma India Ltd Q1 FY26 results?

What is Astrazeneca Pharma India Ltd share price analysis?

Astrazeneca Pharma India Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 106.0 with a market cap of ₹20,271 Cr. Investors should review the full earnings analysis for detailed insights.

Is Astrazeneca Pharma India Ltd planning capital expenditure?

The Company continues to evaluate investments needed in India periodically.

Keep Astrazeneca Pharma India Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.